File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Results of treatment of lymphoblastic lymphoma in children and adolescents of Hong Kong

TitleResults of treatment of lymphoblastic lymphoma in children and adolescents of Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 210, abstract no. PUB-0107 How to Cite?
AbstractPURPOSE/OBJECTIVE: Lymphoblastic lymphoma is one of the major subtypes of childhood non-Hodgkin lymphoma. We aim to review the treatment results of T cell and B cell lymphoblastic lymphoma in children and adolescents of Hong Kong. MATERIALS AND METHODS: The five hospitals forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) treated children and adolescents with lymphoblastic lymphoma using successive treatment protocols for acute lymphoblastic leukaemia from 1995-2008 and a protocol based on EURO-LB02 study from 2008. The clinical data of all cases diagnosed between 1-Mar-1995 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: During the study period, a total of 42 patients including 34 T cell (T-LBL) and 8 B cell (B-LBL) cases were diagnosed. Thirty-one (74%) were males. The median age was 10.4 years (range, 3.0 to 17.7 years). The median follow up duration was 7.0 years (range, 0.08 to 17.5 years). The Murphy stages consisted of 7% stage 1 (n ? 3), 10% stage 2 (n ? 4), 43% stage 3 (n ? 18) and 40% stage 4 (n ? 17). The 5-year event-free survival (EFS) and overall survival (S) were 66.3% and 76.7%, with those for T-LBL 60.3% and 73.7% and for B-LBL 87.5% and 87.5%, respectively. The 5-year EFS and S for stage 1 and 2 cases were both 100% whilst those for stage 3 were 76.9% and 72.3% and for stage 4 47.1% and 70.6%, respectively (p = 0.038 for stage 4 v stage 1-2). All 3 cases with primary refractory disease died. Only 3 of 9 cases with relapsed disease could be salvaged with second line chemotherapy followed by allogeneic stem cell transplantation. CONCLUSIONS: Although survival of LBL with contemporary treatment reaches >70%, stage 3 or 4 lymphoblastic lymphoma which is refractory to treatment or relapses has very poor prognosis.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Abstract submission: Publication only: abstract no. PUB-0107
Persistent Identifierhttp://hdl.handle.net/10722/197715
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorChiang, AKen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorYuen, HLen_US
dc.contributor.authorLi, CHen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLee, ACWen_US
dc.date.accessioned2014-05-29T08:45:06Z-
dc.date.available2014-05-29T08:45:06Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 210, abstract no. PUB-0107en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/197715-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionAbstract submission: Publication only: abstract no. PUB-0107-
dc.description.abstractPURPOSE/OBJECTIVE: Lymphoblastic lymphoma is one of the major subtypes of childhood non-Hodgkin lymphoma. We aim to review the treatment results of T cell and B cell lymphoblastic lymphoma in children and adolescents of Hong Kong. MATERIALS AND METHODS: The five hospitals forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) treated children and adolescents with lymphoblastic lymphoma using successive treatment protocols for acute lymphoblastic leukaemia from 1995-2008 and a protocol based on EURO-LB02 study from 2008. The clinical data of all cases diagnosed between 1-Mar-1995 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: During the study period, a total of 42 patients including 34 T cell (T-LBL) and 8 B cell (B-LBL) cases were diagnosed. Thirty-one (74%) were males. The median age was 10.4 years (range, 3.0 to 17.7 years). The median follow up duration was 7.0 years (range, 0.08 to 17.5 years). The Murphy stages consisted of 7% stage 1 (n ? 3), 10% stage 2 (n ? 4), 43% stage 3 (n ? 18) and 40% stage 4 (n ? 17). The 5-year event-free survival (EFS) and overall survival (S) were 66.3% and 76.7%, with those for T-LBL 60.3% and 73.7% and for B-LBL 87.5% and 87.5%, respectively. The 5-year EFS and S for stage 1 and 2 cases were both 100% whilst those for stage 3 were 76.9% and 72.3% and for stage 4 47.1% and 70.6%, respectively (p = 0.038 for stage 4 v stage 1-2). All 3 cases with primary refractory disease died. Only 3 of 9 cases with relapsed disease could be salvaged with second line chemotherapy followed by allogeneic stem cell transplantation. CONCLUSIONS: Although survival of LBL with contemporary treatment reaches >70%, stage 3 or 4 lymphoblastic lymphoma which is refractory to treatment or relapses has very poor prognosis.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleResults of treatment of lymphoblastic lymphoma in children and adolescents of Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailChiang, AK: chiangak@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.authorityChiang, AK=rp00403en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros229024en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage210-
dc.identifier.epage210-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats